NDA 020487 · Glaxosmithkline
Valtrex
Valacyclovir Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Jun 23, 1995
Approved uses
2
Original approval plus efficacy supplements
Registered trials
141
22 Phase 3, 15 recruiting
FAERS reports
46,257
33,410 serious, 3,756 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
VALTREX is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1−infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1−infected patients. 1.1 Adult Patients Cold Sores (Herpes Labialis) VALTREX is indicated for treatment of cold sores (herpes labialis). The efficacy of VALTREX initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established. Genital Herpes Initial Episode: VALTREX is indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 72 hours after the onset of signs and symptoms has not been established. Recurrent Episodes: VALTREX is indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 24 hours after the onset of signs and symptoms has not been established. Suppressive Therapy: VALTREX is indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-1−infected adults. The efficacy and safety of VALTREX for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-1−infected patients have not been established. Reduction of Transmission: VALTREX is indicated for the reduction of...
Mechanism: Valacyclovir is an antiviral drug active against α-herpes viruses [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 2, 2008 Supplement 14 · Efficacy · priority review LetterLabel
- Jun 23, 1995 Original approval · Type 2 - New Active Ingredient Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Clinical Pharmacology Review
2 products under this application
- VALTREX · VALACYCLOVIR HYDROCHLORIDE EQ 500MG BASE · TABLET, ORAL · Prescription · TE AB
- VALTREX · VALACYCLOVIR HYDROCHLORIDE EQ 1GM BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Valacyclovir" as an intervention, any sponsor and status, largest first.
- A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001038 · 1,200 participants · Primary completion May 1996
Drug: Valacyclovir hydrochloride; Acyclovir · For: Cytomegalovirus Infections; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 35 sites in all
- Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital HerpesPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00306787 · 1,179 participants · Start Mar 2006 · Primary completion Feb 2008
Drug: Famciclovir; Valacyclovir and 2 more · For: Genital Herpes
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 66 sites in all
- A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's PalsyPivotal-lookingCompleted
Wenzhou Medical UniversityAcademic, hospital or other
NCT01686464 · 882 participants · Start Jun 1998 · Primary completion Jan 2005
Drug: prednisone and valacyclovir treatments · For: Bell's Palsy
Sites: Xi’an, China
- Scandinavian Bell's Palsy StudyPivotal-lookingCompleted
Uppsala University HospitalAcademic, hospital or other
NCT00510263 · 839 participants · Start May 2001 · Primary completion Sep 2007
Drug: Prednisolone + placebo; Valaciclovir + placebo and 2 more · For: Bell's Palsy
- Phase III Study of ASP2151 in Herpes Zoster PatientsPivotal-lookingCompleted
Maruho Co., Ltd.Industry
NCT01959841 · 751 participants · Start Aug 2013 · Primary completion Jul 2015
Drug: ASP2151; valaciclovir · For: Herpes Zoster
Sites: Sapporo, Japan; Yokohama, Japan; Nakano-Ku, Japan
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerPivotal-lookingActive, not recruiting
Candel Therapeutics, Inc.Industry
NCT01436968 · 711 participants (planned) · Start Sep 2011 · Primary completion Aug 2024
Drug: Aglatimagene besadenovec + valacyclovir; Placebo + valacyclovir · For: Prostate Cancer
Sites: Gilbert, Arizona; Glendale, Arizona; Peoria, Arizona · 73 sites in all
- A Study With ASP2151 in Subjects With Recurrent Episodes of Genital HerpesPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00486200 · 695 participants · Start Jun 21, 2007 · Primary completion Aug 12, 2008
Drug: ASP2151; valacyclovir and 1 more · For: Herpes Genitalis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 25 sites in all
- Zoster Eye Disease StudyPivotal-lookingCompleted
NYU Langone HealthAcademic, hospital or other
NCT03134196 · 527 participants · Start Aug 23, 2017 · Primary completion Dec 31, 2023
Drug: Masked Placebo; Masked Oral Valacyclovir · For: Herpes Zoster Ophthalmicus
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 78 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,802
- nausea2,783
- fatigue2,678
- off label use2,480
- diarrhoea2,261
- headache2,071
- pyrexia2,056
- pain1,833
- dizziness1,622
- vomiting1,562
- pneumonia1,516
- rash1,458
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 708 |
| 2005 | 798 |
| 2006 | 898 |
| 2007 | 1,057 |
| 2008 | 1,190 |
| 2009 | 1,149 |
| 2010 | 1,173 |
| 2011 | 1,241 |
| 2012 | 1,500 |
| 2013 | 1,127 |
| 2014 | 1,205 |
| 2015 | 1,893 |
| 2016 | 2,107 |
| 2017 | 1,692 |
| 2018 | 1,881 |
| 2019 | 2,199 |
| 2020 | 2,361 |
| 2021 | 2,984 |
| 2022 | 4,618 |
| 2023 | 4,268 |
| 2024 | 4,135 |
| 2025 | 3,689 |
| 2026 | 2,382 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Valtrex (Valacyclovir HCl)
2024 spending
$4.3M
Beneficiaries
1,209
4,107 claims
Per beneficiary
$3,551
$16.37 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,304,186 |
| 2021 | $4,974,775 |
| 2022 | $4,932,787 |
| 2023 | $4,857,102 |
| 2024 | $4,293,428 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.
Cohen EJ, Troxel AB, Liu M, et al. · JAMA Ophthalmol 2025 · Clinical Trial, Phase IV, Multicenter Study
- Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases.
Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, et al. · J Clin Pharm Ther 2021 · Systematic Review
- Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review.
Mancini A, Inchingolo AM, Marinelli G, et al. · Int J Mol Sci 2025 · Systematic Review
- Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis.
Putera I, Ridwan AS, Dewi M, et al. · Surv Ophthalmol 2024 · Meta-Analysis, Systematic Review
- Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis.
D'Antonio F, Marinceu D, Prasad S, et al. · Ultrasound Obstet Gynecol 2023 · Meta-Analysis, Systematic Review
- Valacyclovir.
· Med Lett Drugs Ther 1996 · Clinical Trial, Multicenter Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.